| Assessment Status | NCPE Assessment process complete |
| HTA ID | - |
| Drug | Cobimetinib |
| Brand | Cotellic® |
| Indication | For use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. |
| Assessment Process | |
| Rapid review commissioned | 19/04/2016 |
| Rapid review completed | 26/04/2016 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 18/07/2016 |
| NCPE assessment completed | 05/01/2017 |
| NCPE assessment outcome | Reimbursement Not Recommended at the Submitted Price. |
The NCPE does not consider cobimetinib (Cotellic®) with vemurafenib (Zelboraf®) cost-effective for the treatment of advanced (unresectable or metastatic) melanoma with the BRAF V600 mutation and therefore it is not recommended for reimbursement at the submitted price.
The HSE has approved reimbursement following confidential price negotiations; April 2018.
